PPIDT00315
Drug Information
| Name | Romosozumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB11866 |
| Type | biotech |
| Indication | Romosozumab is indicated for the treatment of osteoporosis in post menopausal women at high risk of fractures and also in patients with osteoperosis who are intolerant to other treatments or who have failed in other treatments[L9554]. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
105 mg/1.17mL
|
| Injection, solution | Subcutaneous |
105 MG
|
| Solution | Subcutaneous |
105 mg / 1.17 mL
|
| Solution | Subcutaneous |
105.000 mg
|
| Solution | Subcutaneous |
105 MG/1.17ML
|
| Solution | Subcutaneous |
9000000 mg
|